Page last updated: 2024-08-21

quinazolines and crizotinib

quinazolines has been researched along with crizotinib in 64 studies

Research

Studies (64)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	63 (98.44)	24.3611
2020's	1 (1.56)	2.80

Authors

Authors	Studies
Friedrich, MJ	1
Moro-Sibilot, D	1
Besse, B; Zalcman, G	1
Giroux Leprieur, E; Planchard, D	1
Goozner, M	1
Kita, K; Mano, H; Matsumoto, K; Nakade, J; Nakagawa, T; Nakamura, T; Nanjo, S; Soda, M; Takeuchi, S; Uenaka, T; Yamada, T; Yano, S	1
Shi, YK	1
Daw, H; Haddad, A; Petrosyan, F; Spiro, T	1
Cai, J; Chen, T; Chen, Y; Deng, J; Du, Z; Li, Q; Lu, J; Shan, B; Song, X; Wery, JP; Yang, M; Zhang, L	1
Ho, WL; Wong, H; Yau, T	1
Aisner, DL; Bunn, PA; Burke, JM; Camidge, DR; Doebele, RC; Gan, G; Gaspar, LE; Kavanagh, BD; Lu, X; Scheier, B; Weickhardt, AJ	1
Besse, B; Chaubet-Houdu, M	1
He, K; Yu, J; Zhang, L; Zheng, X	1
Huber, RM; Reck, M; Thomas, M	1
Couraud, S	1
Bacus, S; Brown, AM; Doherty, KR; Kramer, JW; Moran, DM; Shell, SA; Talbert, DR; Trusk, PB; Wappel, RL	1
Carr, LL; Jett, JR	1
Bae, MK; Cho, BC; Haack, H; Hwang, SK; Jewell, SS; Kang, DR; Kim, HJ; Kim, HR; Kim, JH; Lim, SM; Ou, SH; Park, JK; Shim, HS; Shin, E; Soo, RA; Wang, J	1
Aieta, M; Bulotta, A; Conteduca, V; Gregorc, V; Improta, G; Lazzari, C; Lerose, R; Tartarone, A; Zupa, A	1
Lou, L; Quan, H; Wang, L; Wang, Q; Xie, C; Zhao, J	1
Chen, JJ; Chen, X; Ma, SN; Zhao, J; Zhou, JY	1
Costa, DB; de Figueiredo-Pontes, LL; Gonzalez, DA; Kobayashi, S; Lucena-Araujo, AR; Nakayama, S; Yamaguchi, N; Yasuda, H	1
Nakagawa, T; Yano, S	1
Ebi, H; Ishikawa, D; Matsumoto, K; Nakagawa, T; Nanjo, S; Nishihara, H; Sano, T; Takeuchi, S; Yamada, T; Yano, S; Yasumoto, K; Zhao, L	1
Bria, E; Garassino, M; Massari, F; Pelosi, G; Peretti, U; Pilotto, S; Tortora, G	1
Bellezza, G; Bennati, C; Chiari, R; Crinò, L; Duranti, S; Ludovini, V; Minotti, V; Pireddu, A	1
Horn, L; Lammers, PE; Lovly, CM	1
Gavine, P; Gu, Y; Liu, C; Liu, YJ; Lv, J; Ni, X; Qian, J; Qian, Z; Shen, D; Su, X; Sun, Y; Xu, Y; Yin, X; Zhan, P; Zhang, J; Zhang, T	1
Song, T; Wu, SX; Yu, W	1
Axel, U; Baska, F; Greff, Z; Gyulavári, P; Ibolya, K; Kéri, G; Orfi, L; Peták, I; Szántai, KC; Szokol, B; Vantus, T; Zoltán, O	1
Yano, S	1
Evangelista, M; Merchant, M; Peng, J; Peterson, D; Raha, D; Settleman, J; Wilson, C; Wilson, TR; Yue, P	1
Ebi, H; Ishikawa, D; Matsumoto, K; Nakade, J; Nakagawa, T; Nanjo, S; Sano, T; Takeuchi, S; Yamada, T; Yano, S; Yasumoto, K; Yonekura, K; Zhao, L	1
Eisenstein, M	1
Brunetti, A; De Rosa, V; Del Vecchio, S; Fonti, R; Gargiulo, S; Gramanzini, M; Greco, A; Iommelli, F; Monti, M; Ortosecco, G; Panico, M	1
Cho, HJ; Chung, DH; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Koh, J; Lee, DS; Lee, SH; Won, JK	1
Anderson, JC; Arafat, W; Bonner, JA; Denton, AJ; Dobelbower, MC; Dussaq, AM; Gilbert, AN; Minnich, DJ; Rohrbach, TD; Welaya, K; Willey, CD	1
Garber, K	1
Canoll, P; Chen, S; Guo, B; Horner, JW; Klingler, S; Paik, JH; Vaseva, AV; Wang, YA; Yan, H; Yao, J; Ying, H; Zhang, L; Zheng, H	1
Ackley, E; Balak, M; Bhang, HE; Caushi, JX; Chiang, DY; Cooke, VG; Hims, MM; Kao, I; Keen, N; Korn, JM; Krishnamurthy Radhakrishna, V; Leary, RJ; Michor, F; Palmer, M; Rakiec, D; Raza, A; Ruddy, DA; Schlabach, MR; Sellers, WR; Shaw, P; Singh, AP; Stegmeier, F; Zhao, R	1
Girard, N	1
Allo, G; Ishizawa, K; John, T; Jurisica, I; Kim, L; Leighl, NB; Li, M; Liu, G; Liu, N; Martin, P; Mascaux, C; Neel, BG; Ng, C; Pham, NA; Pintilie, M; Sakashita, S; Shepherd, FA; Stewart, EL; Sykes, J; Tsao, MS; Waddell, TK; Wang, D; Yanagawa, N; Zhu, CQ	1
Asano, H; Hashida, S; Maki, Y; Miyoshi, S; Miyoshi, Y; Ohtsuka, T; Shien, K; Soh, J; Suzawa, K; Toyooka, S; Tsukuda, K; Watanabe, M; Yamamoto, H	1
Azzoli, CG	1
Nishio, K; Togashi, Y	1
Dalgleish, A; Ioannou, N; Mackintosh, D; Modjtahedi, H; Seddon, AM; Solca, F	1
Groen, HJ; Hiltermann, TJ; Kok, K; Saber, A; van den Berg, A; van der Wekken, AJ	1
Watanabe, A	1
Abe, T; Hirata, A; Ito, H; Mano, N; Sato, T; Yamaguchi, H	1
Diebold, J; Froesch, P; Früh, M; Gautschi, O; Jochum, W; Klingbiel, D; Mark, M; Reichegger, H; Rothschild, S; Schmid, S	1
Bonsignore, R; Gentile, C; Lauria, A; Martorana, A	1
Aggarwal, C; Borghaei, H	1
Benveniste, MF; de Groot, PM; Papadimitrakopoulou, VA; Shroff, GS; Truong, MT; Viswanathan, C; Wu, CC	1
Fukushima, T; Gomi, D; Katou, A; Kobayashi, T; Koizumi, T; Mamiya, K; Oguchi, K; Sekiguchi, N; Tateishi, K	1
Fan, T; Liu, XL; Song, YJ; Wei, YN; Yang, H; Zhou, J	1
Komada, F	1
Miyoshi, S; Namba, K; Sakaguchi, M; Sato, H; Shien, K; Soh, J; Suzawa, K; Takeda, T; Tomida, S; Torigoe, H; Toyooka, S; Tsukuda, K; Yamamoto, H; Yoshioka, T	1
Han, R; He, Y; Jiao, L; Li, L; Wang, Y; Zheng, J	1
Chen, M; Tong, B; Wang, M; Xing, J; Xu, Y; Zhao, J; Zhong, W	1
Alexandre, J; Allard, M; Arrondeau, J; Bellesoeur, A; Blanchet, B; Boudou-Rouquette, P; Chapron, J; Giraud, F; Goldwasser, F; Labat, L; Reis, R; Thomas-Schoemann, A; Vidal, M	1
Goto, K; Hotta, K; Ichihara, E; Kato, Y; Kiura, K; Kubo, T; Kudo, K; Maeda, Y; Makimoto, G; Matsumoto, S; Ninomiya, K; Ninomiya, T; Ohashi, K; Sato, A; Tabata, M; Tomida, S; Toyooka, S; Umemura, S; Watanabe, H	1
Han, B; Qiao, R; Wang, S; Xu, J; Zhang, B; Zhang, L; Zhang, Y; Zhao, Y	1
Gao, J; Li, X; Liu, Z; Teng, Y; Yin, P; Yu, P	1

Reviews

15 review(s) available for quinazolines and crizotinib

Article	Year
Targeted therapy for lung cancer. Anti-cancer drugs, 2012, Volume: 23, Issue:10 Topics: Animals; Carcinoma, Non-Small-Cell Lung; Crizotinib; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Targeted Therapy; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines	2012
The ophthalmological complications of targeted agents in cancer therapy: what do we need to know as ophthalmologists? Acta ophthalmologica, 2013, Volume: 91, Issue:7 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Benzamides; Bevacizumab; Cetuximab; Crizotinib; Erlotinib Hydrochloride; Eye Diseases; Humans; Imatinib Mesylate; Molecular Targeted Therapy; Neoplasms; Phosphorylcholine; Piperazines; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Trastuzumab	2013
[Brain metastases of non small cell lung cancers: systemic treatments]. Bulletin du cancer, 2013, Jan-01, Volume: 100, Issue:1 Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Crizotinib; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Pyrazoles; Pyridines; Quinazolines	2013
Current status of and future strategies for multimodality treatment of unresectable stage III nonsmall cell lung cancer. The European respiratory journal, 2013, Volume: 42, Issue:4 Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Cetuximab; Chemoradiotherapy; Clinical Trials as Topic; Combined Modality Therapy; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Evidence-Based Medicine; Gefitinib; Humans; Immunotherapy; Lung Neoplasms; Pyrazoles; Pyridines; Quinazolines	2013
Targeted therapy for non-small cell lung cancer. American journal of respiratory and critical care medicine, 2013, Oct-15, Volume: 188, Issue:8 Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Therapy, Combination; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Molecular Targeted Therapy; Pyrazoles; Pyridines; Quinazolines	2013
Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib. Lung cancer (Amsterdam, Netherlands), 2013, Volume: 81, Issue:3 Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases	2013
Subsequent treatment choices for patients with acquired resistance to EGFR-TKIs in non-small cell lung cancer: restore after a drug holiday or switch to another EGFR-TKI? Asian Pacific journal of cancer prevention : APJCP, 2014, Volume: 15, Issue:1 Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drug Substitution; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Retreatment	2014
[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy]. Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3 Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Crizotinib; Drug Discovery; Education, Medical, Continuing; Erlotinib Hydrochloride; Etoposide; Gefitinib; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma	2014
Practical Value of Molecular Pathology in Stage I-III Lung Cancer: Implications for the Clinical Surgeon. Annals of surgical oncology, 2015, Volume: 22, Issue:11 Topics: Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases	2015
[Kinase inhibitors and their resistance]. Nihon rinsho. Japanese journal of clinical medicine, 2015, Volume: 73, Issue:8 Topics: Antibodies, Monoclonal, Humanized; Benzamides; Biomarkers, Tumor; Crizotinib; Drug Discovery; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Signal Transduction; Sorafenib; Sulfonamides; Trastuzumab; Vemurafenib	2015
Resistance mechanisms after tyrosine kinase inhibitors afatinib and crizotinib in non-small cell lung cancer, a review of the literature. Critical reviews in oncology/hematology, 2016, Volume: 100 Topics: Afatinib; Animals; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases	2016
[Companion Diagnostics for Solid Tumors]. Rinsho byori. The Japanese journal of clinical pathology, 2015, Volume: 63, Issue:11 Topics: Anaplastic Lymphoma Kinase; Biomarkers, Tumor; Breast Neoplasms; Cetuximab; Colonic Neoplasms; Crizotinib; Diagnostic Uses of Chemicals; Drug Discovery; ErbB Receptors; Gefitinib; Gene Fusion; Guidelines as Topic; Humans; Lung Neoplasms; Molecular Diagnostic Techniques; Molecular Targeted Therapy; Pharmacogenetics; Precision Medicine; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Trastuzumab	2015
Kinase Inhibitors in Multitargeted Cancer Therapy. Current medicinal chemistry, 2017, Volume: 24, Issue:16 Topics: Anilides; Crizotinib; Humans; Imatinib Mesylate; Imidazoles; Indoles; Neoplasms; Niacinamide; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Pyrazoles; Pyridazines; Pyridines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Sorafenib; Sunitinib	2017
Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design. The oncologist, 2017, Volume: 22, Issue:6 Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Disease-Free Survival; Drug Approval; Endpoint Determination; Humans; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Sulfones	2017
Targeted Therapy and Imaging Findings. Journal of thoracic imaging, 2017, Volume: 32, Issue:5 Topics: Angiogenesis Inhibitors; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Crizotinib; Diagnostic Imaging; Gefitinib; Humans; Lung; Lung Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines	2017

Trials

1 trial(s) available for quinazolines and crizotinib

Article	Year
Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer. Medical oncology (Northwood, London, England), 2017, Sep-01, Volume: 34, Issue:10 Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome	2017

Article

Year

Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer.

Medical oncology (Northwood, London, England), 2017, Sep-01, Volume: 34, Issue:10

Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Female; Fluorodeoxyglucose F18; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome

2017

Other Studies

48 other study(ies) available for quinazolines and crizotinib

Article	Year
NSCLC drug targets acquire new visibility. Journal of the National Cancer Institute, 2011, Mar-02, Volume: 103, Issue:5 Topics: Antineoplastic Agents; Benzenesulfonates; Benzimidazoles; Bexarotene; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Niacinamide; Oncogene Proteins, Fusion; Phenylurea Compounds; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Randomized Controlled Trials as Topic; Sorafenib; Tetrahydronaphthalenes; Treatment Outcome	2011
[What choice of first-line treatment?]. Revue de pneumologie clinique, 2011, Volume: 67 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Evidence-Based Medicine; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Survival Analysis; Translocation, Genetic	2011
[What is the best sequence of treatment for patients with EGFR mutations?]. Revue de pneumologie clinique, 2011, Volume: 67 Suppl 1 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; Disease-Free Survival; Drug Administration Schedule; ErbB Receptors; Evidence-Based Medicine; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Mutation; Neoplasm Staging; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quality of Life; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Treatment Outcome	2011
[Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments]. Revue de pneumologie clinique, 2011, Volume: 67 Suppl 1 Topics: Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; ErbB Receptors; Gefitinib; Gene Amplification; Genes, erbB-1; Humans; Lung Neoplasms; Medical Oncology; Mutation; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome	2011
Drug approvals 2011: focus on companion diagnostics. Journal of the National Cancer Institute, 2012, Jan-18, Volume: 104, Issue:2 Topics: Androstenes; Androstenols; Antibodies, Monoclonal; Antineoplastic Agents; Axitinib; Biomarkers, Tumor; Brentuximab Vedotin; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Drug Approval; Female; Humans; Imidazoles; Immunoconjugates; Indazoles; Indoles; Ipilimumab; Lung Neoplasms; Male; Melanoma; Molecular Targeted Therapy; Neoplasms; Piperidines; Prostatic Neoplasms; Pyrazoles; Pyridines; Quinazolines; Rare Diseases; Sulfonamides; Survival Analysis; United States; United States Food and Drug Administration; Vemurafenib	2012
Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, Jul-01, Volume: 18, Issue:13 Topics: Adaptor Proteins, Signal Transducing; Anaplastic Lymphoma Kinase; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Coculture Techniques; Crizotinib; Drug Resistance, Neoplasm; Endothelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Fibroblasts; Gene Amplification; Hepatocyte Growth Factor; Humans; Intercellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Mice; Mice, SCID; Mutation, Missense; Oncogene Proteins, Fusion; Paracrine Communication; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Tumor Microenvironment; Xenograft Model Antitumor Assays	2012
[Current status and perspectives of individualized therapy for non-small cell lung cancer based on molecular targeting]. Zhonghua zhong liu za zhi [Chinese journal of oncology], 2012, Volume: 34, Issue:5 Topics: Animals; Antibodies, Monoclonal; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Immunoglobulins, Intravenous; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quality Control; Quinazolines	2012
Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients. International journal of cancer, 2013, Jan-15, Volume: 132, Issue:2 Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Asian People; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crizotinib; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Oligonucleotide Array Sequence Analysis; Point Mutation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Transcriptome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2013
Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:12 Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Catheter Ablation; Combined Modality Therapy; Crizotinib; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Retrospective Studies; Survival Rate; Young Adult	2012
Crizotinib induces PUMA-dependent apoptosis in colon cancer cells. Molecular cancer therapeutics, 2013, Volume: 12, Issue:5 Topics: Animals; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; Colonic Neoplasms; Crizotinib; Drug Synergism; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Mice; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Quinazolines; Sorafenib; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays	2013
[About new treatments in thoracic oncology]. Revue de pneumologie clinique, 2013, Volume: 69, Issue:2 Topics: Afatinib; Antineoplastic Agents; Crizotinib; DNA Mutational Analysis; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Markers; Humans; Lung Neoplasms; Oncogene Proteins, Fusion; Prognosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines	2013
Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes. Toxicology and applied pharmacology, 2013, Oct-01, Volume: 272, Issue:1 Topics: Caspase 3; Caspase 7; Cell Survival; Cells, Cultured; Cholesterol; Crizotinib; Enzyme Activation; ERG1 Potassium Channel; Erlotinib Hydrochloride; Ether-A-Go-Go Potassium Channels; Humans; Indoles; Ion Channels; Lipids; Myocytes, Cardiac; Patch-Clamp Techniques; Pluripotent Stem Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; RNA; Sunitinib	2013
The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Annals of oncology : official journal of the European Society for Medical Oncology, 2013, Volume: 24, Issue:9 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Anaplastic Lymphoma Kinase; Antigens, Differentiation, B-Lymphocyte; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; Crizotinib; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Frequency; Gene Rearrangement; Glutamates; Guanine; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Pemetrexed; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Pyrimidines; Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Recombinant Fusion Proteins; Reverse Transcriptase Polymerase Chain Reaction; Smoking; Treatment Outcome	2013
RON confers lapatinib resistance in HER2-positive breast cancer cells. Cancer letters, 2013, Oct-28, Volume: 340, Issue:1 Topics: Anilides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Crizotinib; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Gene Knockdown Techniques; Humans; Inhibitory Concentration 50; Lapatinib; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Pyrazoles; Pyridines; Quinazolines; Quinolines; Receptor Protein-Tyrosine Kinases; Receptor, ErbB-2; Signal Transduction; Trastuzumab	2013
Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells. Anti-cancer drugs, 2013, Volume: 24, Issue:10 Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Crizotinib; Drug Resistance, Neoplasm; Drug Synergism; ErbB Receptors; Female; Gefitinib; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Mice, SCID; Mutation; Pyrazoles; Pyridines; Quinazolines; Xenograft Model Antitumor Assays	2013
Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer. Lung cancer (Amsterdam, Netherlands), 2014, Volume: 83, Issue:1 Topics: Afatinib; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Cell Growth Processes; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Gene Amplification; Gene Rearrangement; Humans; Lung Neoplasms; Microarray Analysis; Mutation; Oncogene Proteins, Fusion; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases	2014
The current state of molecularly targeted drugs targeting HGF/Met. Japanese journal of clinical oncology, 2014, Volume: 44, Issue:1 Topics: Acrylamides; Afatinib; Aminopyridines; Antibodies, Monoclonal; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; Drugs, Investigational; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasms; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Pyrrolidinones; Quinazolines; Quinolines; Signal Transduction; Up-Regulation; Vascular Endothelial Growth Factor Receptor-2	2014
Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. PloS one, 2013, Volume: 8, Issue:12 Topics: Acrylamides; Afatinib; Amino Acid Substitution; Animals; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, SCID; Mutation, Missense; Phosphorylation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Xenograft Model Antitumor Assays	2013
Lung adenocarcinoma patient refractory to gefitinib and responsive to crizotinib, with concurrent rare mutation of the epidermal growth factor receptor (L861Q) and increased ALK/MET/ROS1 gene copy number. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013, Volume: 8, Issue:12 Topics: Adenocarcinoma; Aged; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; DNA, Neoplasm; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Gene Dosage; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Salvage Therapy	2013
Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2014, Mar-20, Volume: 32, Issue:9 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Antineoplastic Combined Chemotherapy Protocols; Crizotinib; Disease Progression; Drug Administration Schedule; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome	2014
A patient with metastatic lung adenocarcinoma harboring concurrent EGFR L858R, EGFR germline T790M, and PIK3CA mutations: the challenge of interpreting results of comprehensive mutational testing in lung cancer. Journal of the National Comprehensive Cancer Network : JNCCN, 2014, Volume: 12, Issue:1 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Mutation; Phosphatidylinositol 3-Kinases; Precision Medicine; Pyrazoles; Pyridines; Quinazolines; Treatment Outcome	2014
HER2, MET and FGFR2 oncogenic driver alterations define distinct molecular segments for targeted therapies in gastric carcinoma. British journal of cancer, 2014, Mar-04, Volume: 110, Issue:5 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Crizotinib; Female; Humans; Lapatinib; Male; Mice; Mice, Nude; Middle Aged; Molecular Targeted Therapy; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Random Allocation; Receptor, ErbB-2; Receptor, Fibroblast Growth Factor, Type 2; Stomach Neoplasms; Xenograft Model Antitumor Assays	2014
[Development and biochemical characterization of EGFR/c-Met dual inhibitors]. Acta pharmaceutica Hungarica, 2013, Volume: 83, Issue:4 Topics: Afatinib; Aminopyridines; Anilides; Antineoplastic Agents; Apoptosis; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line; Cell Line, Tumor; Computer Simulation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Imidazoles; Lapatinib; Lung Neoplasms; Molecular Structure; Protein Kinase Inhibitors; Protein Kinases; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-met; Pyrazines; Pyrazoles; Pyridines; Pyridones; Quinazolines; Quinolines	2013
The cancer stem cell marker aldehyde dehydrogenase is required to maintain a drug-tolerant tumor cell subpopulation. Cancer research, 2014, Jul-01, Volume: 74, Issue:13 Topics: Aldehyde Dehydrogenase; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Crizotinib; Disulfiram; DNA Damage; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Humans; Mice; Mice, Nude; Neoplastic Stem Cells; Oxidative Stress; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Reactive Oxygen Species; RNA Interference; RNA, Small Interfering; Xenograft Model Antitumor Assays	2014
Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:6 Topics: Adenocarcinoma; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cell Line, Tumor; Cell Proliferation; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Hepatocyte Growth Factor; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Neovascularization, Pathologic; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Quinolines; Thiourea; Vascular Endothelial Growth Factor A	2014
Clinical trials: More trials, fewer tribulations. Nature, 2014, May-29, Volume: 509, Issue:7502 Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Clinical Trials as Topic; Crizotinib; DNA Mutational Analysis; Drug Approval; Drug Resistance, Neoplasm; Female; Gefitinib; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Neoplasms; Patient Selection; Proto-Oncogene Proteins B-raf; Pyrazoles; Pyridines; Quinazolines; Quinolines; Sample Size	2014
Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography. Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Sep-15, Volume: 20, Issue:18 Topics: Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Fluorine Radioisotopes; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Positron-Emission Tomography; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Radiopharmaceuticals; RNA Interference; Xenograft Model Antitumor Assays	2014
Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor. Annals of oncology : official journal of the European Society for Medical Oncology, 2015, Volume: 26, Issue:2 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; DNA Mutational Analysis; Female; Gefitinib; Genes, erbB-1; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor Protein-Tyrosine Kinases; Sensitivity and Specificity; Sulfones; Translocation, Genetic	2015
Kinomic profiling of electromagnetic navigational bronchoscopy specimens: a new approach for personalized medicine. PloS one, 2014, Volume: 9, Issue:12 Topics: Aged; Aged, 80 and over; Bronchoscopy; Crizotinib; Electromagnetic Phenomena; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Humans; Lapatinib; Lung Neoplasms; Male; Middle Aged; Phosphotransferases; Precision Medicine; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines	2014
Oncologists push beyond new lung cancer genomic testing guidelines. Journal of the National Cancer Institute, 2015, Volume: 107, Issue:2 Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Genomics; Humans; Lung Neoplasms; Medical Oncology; Molecular Targeted Therapy; Mutation; Practice Guidelines as Topic; Precision Medicine; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Societies, Medical; Sulfones; Translocation, Genetic	2015
Development of Resistance to EGFR-Targeted Therapy in Malignant Glioma Can Occur through EGFR-Dependent and -Independent Mechanisms. Cancer research, 2015, May-15, Volume: 75, Issue:10 Topics: Animals; Brain Neoplasms; Crizotinib; Cyclin-Dependent Kinase Inhibitor p16; Doxycycline; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Glioma; Humans; Imidazoles; Mice, Inbred C57BL; Mice, Transgenic; Molecular Targeted Therapy; Phosphorylation; Protein Processing, Post-Translational; PTEN Phosphohydrolase; Pyrazoles; Pyridines; Quinazolines; Quinolines; Tumor Cells, Cultured	2015
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding. Nature medicine, 2015, Volume: 21, Issue:5 Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Differentiation; Cell Line, Tumor; Crizotinib; DNA; DNA Barcoding, Taxonomic; DNA, Complementary; Epithelial-Mesenchymal Transition; Erlotinib Hydrochloride; Fusion Proteins, bcr-abl; Gene Dosage; Gene Library; Humans; Lung Neoplasms; Models, Theoretical; Neoplasms; Oligonucleotides; Polymerase Chain Reaction; Proto-Oncogene Proteins c-abl; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Sequence Analysis, RNA	2015
[Is chemotherapy still an option in oncogene-addicted non-small cell lung cancer? No]. Bulletin du cancer, 2015, Volume: 102, Issue:6 Suppl 1 Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases	2015
Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Aug-01, Volume: 33, Issue:22 Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Aged, 80 and over; Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cetuximab; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Heterografts; Humans; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, SCID; Middle Aged; Mutation; Predictive Value of Tests; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Quinazolinones; Signal Transduction; Up-Regulation	2015
Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib. Cancer science, 2015, Volume: 106, Issue:10 Topics: Afatinib; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Base Sequence; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Crizotinib; DNA Methylation; Docetaxel; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Mice, SCID; MicroRNAs; Mutation; Neoplastic Stem Cells; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyrazoles; Pyridines; Quinazolines; Retinal Dehydrogenase; Sequence Analysis, DNA; Taxoids	2015
Singapore Cancer Network (SCAN) Guidelines for the Use of Systemic Therapy in Advanced Non-Small Cell Lung Cancer. Annals of the Academy of Medicine, Singapore, 2015, Volume: 44, Issue:10 Topics: Adenocarcinoma; Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Crizotinib; Docetaxel; Erlotinib Hydrochloride; Gefitinib; Genes, erbB-1; Humans; Lung Neoplasms; Maintenance Chemotherapy; Pemetrexed; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Singapore; Taxoids; Translocation, Genetic	2015
Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition. International journal of oncology, 2016, Volume: 48, Issue:3 Topics: Afatinib; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Crizotinib; Cyclic S-Oxides; Deoxycytidine; DNA Mutational Analysis; Drug Resistance, Neoplasm; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Inhibitory Concentration 50; Ligands; MAP Kinase Signaling System; Mutation; Pancreatic Neoplasms; Phenotype; Phosphorylation; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Signal Transduction; STAT3 Transcription Factor	2016
Interactions of crizotinib and gefitinib with organic anion-transporting polypeptides (OATP)1B1, OATP1B3 and OATP2B1: gefitinib shows contradictory interaction with OATP1B3. Xenobiotica; the fate of foreign compounds in biological systems, 2018, Volume: 48, Issue:1 Topics: Crizotinib; Drug Interactions; Gefitinib; HEK293 Cells; Humans; Liver; Liver-Specific Organic Anion Transporter 1; Organic Anion Transporters; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines	2018
Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017, Volume: 12, Issue:4 Topics: Adenocarcinoma; Adult; Afatinib; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gene Rearrangement; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Staging; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins p21(ras); Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Survival Rate	2017
Lung Cancer with Concomitant Double Gene Mutation. Journal of the College of Physicians and Surgeons--Pakistan : JCPSP, 2018, Volume: 28, Issue:1 Topics: Adenocarcinoma; Anaplastic Lymphoma Kinase; Antibodies, Monoclonal; Biopsy; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; ErbB Receptors; Female; Humans; Lung Neoplasms; Molecular Targeted Therapy; Mutation; Neoplasm Staging; Nivolumab; Pemetrexed; Positron Emission Tomography Computed Tomography; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Reverse Transcriptase Polymerase Chain Reaction; Treatment Outcome	2018
[Analysis of Time-to-onset of Interstitial Lung Disease after the Administration of Small Molecule Molecularly-targeted Drugs]. Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan, 2018, Volume: 138, Issue:2 Topics: Adverse Drug Reaction Reporting Systems; Afatinib; Bortezomib; Carbazoles; Cluster Analysis; Crizotinib; Dasatinib; Databases as Topic; Datasets as Topic; Drug-Related Side Effects and Adverse Reactions; Humans; Japan; Lung Diseases, Interstitial; Molecular Targeted Therapy; Particle Size; Piperidines; Pyrazoles; Pyridines; Quinazolines; Time Factors	2018
Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations. Cancer science, 2018, Volume: 109, Issue:5 Topics: Afatinib; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Docetaxel; Drug Resistance, Neoplasm; Female; Gene Amplification; Humans; Lung Neoplasms; Mice; Neoplastic Stem Cells; Proto-Oncogene Proteins c-met; Pyrazoles; Pyridines; Quinazolines; Receptor, ErbB-2; Taxoids; Treatment Outcome; Xenograft Model Antitumor Assays	2018
Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib. Lung cancer (Amsterdam, Netherlands), 2018, Volume: 118 Topics: Acrylamides; Adenocarcinoma of Lung; Adult; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinogenesis; Cohort Studies; Crizotinib; Crown Ethers; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Amplification; High-Throughput Nucleotide Sequencing; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Piperazines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Quinazolines; Survival Analysis	2018
Prognostic role of circulating tumor cells in patients with EGFR-mutated or ALK-rearranged non-small cell lung cancer. Thoracic cancer, 2018, Volume: 9, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Cell Count; Crizotinib; Crown Ethers; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Gene Rearrangement; Humans; Male; Middle Aged; Molecular Targeted Therapy; Neoplastic Cells, Circulating; Prognosis; Quinazolines	2018
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the EGFR inhibitors afatinib, erlotinib and osimertinib, the ALK inhibitor crizotinib and the VEGFR inhibitor nintedanib in human plasma from non-small cell lung canc Journal of pharmaceutical and biomedical analysis, 2018, Sep-05, Volume: 158 Topics: Acrylamides; Afatinib; Aniline Compounds; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chromatography, High Pressure Liquid; Crizotinib; Drug Monitoring; Drug Stability; ErbB Receptors; Erlotinib Hydrochloride; Humans; Indoles; Limit of Detection; Lung Neoplasms; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results; Sensitivity and Specificity; Tandem Mass Spectrometry	2018
Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. Cancer science, 2018, Volume: 109, Issue:10 Topics: Anilides; Animals; Antigens, Differentiation, B-Lymphocyte; Antineoplastic Combined Chemotherapy Protocols; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Heparin-binding EGF-like Growth Factor; Histocompatibility Antigens Class II; Humans; Lung Neoplasms; Mice; Mice, Inbred NOD; Oncogene Proteins, Fusion; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Sodium-Phosphate Cotransporter Proteins, Type IIb; Up-Regulation; Xenograft Model Antitumor Assays	2018
Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib. Targeted oncology, 2019, Volume: 14, Issue:2 Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Crizotinib; Crown Ethers; ErbB Receptors; Erlotinib Hydrochloride; Female; Follow-Up Studies; Gefitinib; Gene Rearrangement; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Prognosis; Quinazolines; Retrospective Studies; Survival Rate; Young Adult	2019
The therapeutic inhibition of topoisomerase inhibitor and crizotinib combination in EGFR wild and mutant lung cancer cells. Biochemical pharmacology, 2022, Volume: 205 Topics: Animals; bcl-2-Associated X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Crizotinib; Drug Resistance, Neoplasm; ErbB Receptors; Lung Neoplasms; p38 Mitogen-Activated Protein Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Reactive Oxygen Species; Topoisomerase Inhibitors; Topotecan	2022